Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + Binimetinib PK in Hepatic Impairment
NCT04759846Phase 1Withdrawn
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of encorafenib in solid tumor and melanoma, sponsored by Pierre Fabre Laboratories. Primary endpoints: Encorafenib Maximum Observed Plasma Concentration at Day 15, Encorafenib Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 15 and 1 more. Planned start Jan 2021; status: withdrawn.
02
Drugs
encorafenib
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT04759846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759846.